Genmab Reports Positive EPCORE FL-1 Data for Epcoritamab Combination
COPENHAGEN, Denmark, June 11, 2026 Genmab A/S announced new subgroup analysis results from the pivotal Phase 3 EPCORE FL-1...
Phase 3 trial
Advertisement
AbbVie Reports 9-Year VENCLEXTA Data in First-Line CLL
NORTH CHICAGO, Ill., June 12, 2026 AbbVie announced new long-term clinical results from the Phase 3 CLL14 trial at...
Jazz Reports Phase 3 LAGOON Results for Zepzelca in SCLC
DUBLIN, Ireland, June 12, 2026 Jazz Pharmaceuticals has announced topline results from the Phase 3 LAGOON trial evaluating Zepzelca®...
DKSH and BridgeBio Partner to Expand ATTR-CM Treatment Access
SINGAPORE, June 11, 2026 DKSH Healthcare and BridgeBio have entered into a strategic distribution and commercialization partnership aimed at...
Takeda’s Zasocitinib Outperforms Deucravacitinib in Psoriasis
STOCKHOLM, Sweden, June 11OSAKA, Japan and CAMBRIDGE, Massachusetts, June 11, 2026, 2026 Takeda has announced positive topline results from...
Advertisements
Takeda’s ENTYVIO Nears Pediatric IBD FDA Approval
OSAKA, Japan and CAMBRIDGE, Massachusetts, June 9, 2026 Takeda has reached a significant regulatory milestone with the U.S. Food...
UCB Receives Favorable Canadian Reimbursement Opinion for BIMZELX
OAKVILLE, Ontario, June 9, 2026 UCB Canada announced that BIMZELX® (bimekizumab injection) received a positive reimbursement recommendation with conditions...
Sanofi Ends Phase 3 MOBILIZE Trial of Riliprubart in CIDP
PARIS, France, June 10, 2026 Sanofi announced that it will discontinue the Phase 3 MOBILIZE study evaluating riliprubart in...
Vertanical’s Exilby Wins First European Approval for Chronic Pain
GRÄFELFING, Germany – June 9, 2026 VERTANICAL has achieved a major milestone in chronic pain treatment after receiving Germany’s...
Pentixapharm Advances PANDA Phase 3 Study After FDA Clearance
BERLIN, Germany – June 9, 2026 Pentixapharm Holding AG has achieved a major regulatory milestone after receiving U.S. Food...
Advertisement
